[Clinical efficacy and perinatal outcome of nifedipine for severe preeclampsia: meta-analysis].

OBJECTIVE: To assess the efficacy, side effects and perinatal outcome of nifedipine compared with other antihypertensives for treating severe preeclampsia in pregnant women. METHODS: Randomized controlled trials (RCTs) that comparing nifedipine with other antihypertensives for severe preeclampsia were searched in PubMed, EMBase, Cochrane library, CNKI and VIP database etc(till January 2012). The quality of the included RCTs was evaluated, and Meta-analysis was performed with Rev Man 5.1 software. RESULTS: Nine trials were included, involving 386 women in the nifedipine group, and 378 women in other antihypertensives group. Compared with other antihypertensives, nifidepine was associated with greater effective control of blood pressure (OR = 2.65, 95%CI: 1.65 - 4.25, P < 0.01). There was no clear difference in the time needed to control blood pressure (WMD = -3.64, 95%CI: -10.90 - 3.61, P = 0.32). Nifedipine could prolong gestation better than other antihypertensives (WMD = 5.14, 95%CI: 3.29 - 6.99, P < 0.01). There were no clear differences in maternal side effects headache (P = 0.28), palpitation (P = 0.06), and nausea vomiting (P = 0.28). No noticeable difference was found between the two groups in the Apgar score at five minutes (WMD = -0.21, 95%CI: -0.32 - 0.91, P = 0.72), neonatal respiratory distress syndrome (OR = 1.24, 95%CI: 0.57 - 2.67, P = 0.59), or perinatal deaths (OR = 0.49, 95%CI: 0.22 - 1.11, P = 0.09). CONCLUSION: Nifedipine is associated with greater effective control of blood pressure and prolongation of gestation, with no additional neonatal respiratory distress syndrome or perinatal deaths, compared with other antihypertensives for women with severe preeclampsia.

Heparin for patients with growth restricted fetus: a prospective randomized controlled trial.

OBJECTIVE: Heparin was hypothesized to facilitate the growth of the growth-restricted fetus. Our study was to assess the efficiency of heparin in treating fetus with growth restriction and to explore the possible mechanisms. METHODS: Seventy-three pregnant women were selected in this study. Based on regular treatments, patients randomly received either heparin or dan-shen combined with low-molecular weight dextrose. A serial ultrasonography and hematological measurements were performed on each patient at the enrolment and 7 days after the first treatment. Neonatal birth weight, 1-min Apgar score and gestational age were recorded. Placentas were collected for apoptotic indices. RESULTS: Heparin significantly improved maternal hemorrheological indices, fetal growth velocities and neonatal outcomes. It also reduced apoptosis in trophoblasts. CONCLUSIONS: Our results provide evidence that heparin significantly improves the growth of the growth-restricted fetus. The growth improvement is probably achieved by the changes in maternal hemorrheology and the attenuated apoptosis in trophoblasts.